Word

LYSOSCORE

Status

Pending

Status Code

681

Status Date

Wednesday, April 24, 2024

Serial Number

79364555

Mark Type

4

Filing Date

Thursday, January 19, 2023

Published for Opposition

Tuesday, May 28, 2024

Trademark Owner History

Samsara Therapeutics

Classifications

44 Medical services, medical diagnostic testing services; medical and pharmaceutical consultancy; medical analysis services relating to the diagnosis and treatment of persons; laboratory analysis services relating to the diagnosis and treatment of persons in the field of neurodegenerative diseases, monogenic diseases, cancer, neurology, immunology, cardiovascular disease, and metabolic diseases; medical examinations; medical screening; Remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; medical testing for diagnostic or treatment purposes in the field of neurodegenerative diseases, monogenic diseases, cancer, neurology, immunology, cardiovascular disease, and metabolic diseases; medical analysis services relating to the treatment of patients for diagnosising and treating illnesses

42 Scientific and technological research in the field of medicine, biotechnology, biology, biomedicine, pharmaceuticals, genetics, molecular sciences, therapeutics, chemistry and biochemistry; Pharmaceutical products development; research and development of new products for others; pharmaceutical drug development services; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics; database services, namely, electronic storage of data in computer databases; design, engineering, research, development and testing services in the field of pharmaceuticals, biotechnology, biology, biomedicine, genetics, molecular sciences, therapeutics, chemistry and biochemistry for medical, scientific, and technological applications; preparation of scientific analysis and evaluations namely, testing of pharmaceuticals and pharmaceutical product evaluation; consultancy relating to research and development in the field of therapeutics; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of pharmacogenetics; development of pharmaceutical preparations and medicines; medical laboratory services

Trademark Events

Oct 25, 2023

Non-Final Action Written

Oct 26, 2023

Non-Final Action (Ib Refusal) Prepared For Review

Mar 9, 2023

Sn Assigned For Sect 66a Appl From Ib

Mar 10, 2023

New Application Office Supplied Data Entered

Mar 14, 2023

Application Filing Receipt Mailed

Oct 17, 2023

Assigned To Examiner

Oct 30, 2023

Refusal Processed By Mpu

Oct 30, 2023

Non-Final Action Mailed - Refusal Sent To Ib

Nov 21, 2023

Refusal Processed By Ib

Mar 4, 2024

Correspondence Received In Law Office

Mar 4, 2024

Teas/Email Correspondence Entered

Mar 4, 2024

Teas Response To Office Action Received

Apr 18, 2024

Examiners Amendment -Written

Apr 18, 2024

Examiners Amendment E-Mailed

Apr 18, 2024

Notification Of Examiners Amendment E-Mailed

Apr 18, 2024

Examiner's Amendment Entered

Apr 18, 2024

Approved For Pub - Principal Register

May 8, 2024

Notification Of Notice Of Publication E-Mailed